PubMed Health⌕ Search

Biomedical subjects

S Lundblad

Publications and source records attributed to S Lundblad.

5 recordsLinked to original sources
PubMed1993

How accurate are home blood-glucose meters with special respect to the low glycemic range?

Comparisons were made between four blood-glucose meters (Diascan, Glucometer II, Reflolux II and ExacTech) and a reference method (YSI) for the full, clinical, blood-glucose range and for the subranges < 4.4 mmol/l, 4.4-10.0 mmol/l and > 10.0 mmol/l, respectively. In the low-glucose range, the error-grid analysis was also applied. All the meters showed acceptable agreement with the reference method when the whole glucose range was considered, yielding r-values between 0.96 and 0.99. However, when the results were separated in the different subranges, the outcome was different, in that the Diascan meter displayed systematically high glucose levels and the ExacTech meter showed a great spread of the values within the low-glucose range, whereas the Glucometer II and the Reflolux II meter were less accurate within the high-glucose range. By applying the error-grid analysis, several errors of clinical importance within the low glycemic range were revealed, while other significant errors, which might lead to inadequate therapeutic decisions, were classified as 'clinically accurate'.

Blood Glucose↗
PubMed1988

Glibenclamide improves the response to insulin treatment in non-insulin-dependent diabetics with second failure to sulfonylurea therapy.

The effect of combined insulin-glibenclamide therapy on glucose control was evaluated in a double-blind placebo controlled study of 20 patients with non-insulin-dependent diabetes mellitus (NIDDM) and second failure to oral antidiabetic therapy with glibenclamide or glipizide. After an observation period of 1-3 months, insulin treatment was initiated which resulted in rapid improvement of the glycemic control within 6 weeks. Thereafter glibenclamide or placebo was added to insulin for a further 12 weeks. Glibenclamide improved the glycemic control as expressed by a diminution of blood glucose and HbA1c. This was observed in spite of the fact that the daily insulin dose was reduced by approximately 30% in the glibenclamide-treated group of patients. It is concluded that in NIDDM patients with second failure to glibenclamide ot glipizide therapy, the responsiveness to glibenclamide may be at least partially restored by a short period of insulin treatment. It is suggested that therapy with insulin and glibenclamide is an appropriate treatment regimen for NIDDM patients with second failure to sulfonylurea therapy.

Adult↗